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Abstract
Background: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b
has been shown to be one of the key factors in determining resistance for pegylated interferon-α plus ribavirin
combination therapy (PEG-IFNα/RBV). But the exact mechanisms remain unclear. The aim of this study was to
investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFNα/RBV treatment.
Methods: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a
standard protocol of 48 weeks of PEG-IFNα/RBV therapy and 24 consecutive weeks of follow-up. Serial blood
samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the
quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response
(EVR), sustained virological response (SVR) and IL28B genotypes were analyzed.
Results: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H
strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant
70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with
dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant
strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to
treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change
significantly during treatment.
Conclusions: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always
exhibited the same response as the 70R strains during PEG-IFNα/RBV treatment. Substitution of R70Q/H alone
is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFNα was not observed.
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Background
Hepatitis C virus (HCV) infection is one of the major
causes of chronic hepatitis and is a global health problem
that affects more than 170 million people. In many coun-
tries, hepatitis C is the leading cause of cirrhosis and
hepatocellular carcinoma (HCC), as well as the leading in-
dication for liver transplantation [1–6]. Of the currently
available treatments for chronic HCV infection in China,
the most effective is the combination of pegylated inter-
feron alfa (PEG-IFNα) and ribavirin (RBV), which repre-
sents a standard treatment approach. However, the long
term response to therapy is not satisfactory, especially in
patients with HCV genotype 1b, even when administered in
a triple therapy regimen available in several countries that
includes direct-acting antivirals (DAAs) for the treatment
of HCV (telaprevir or boceprevir).
Several factors have been determined to be associated
with the failure to respond to PEG-IFNα/RBV therapy
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and post-treatment relapse, including interleukin 28B single
nucleotide polymorphisms (IL28B SNPs), gender, race, age,
obesity [7–11], HCV genotypes, viral load, amino acid sub-
stitution in the CORE region, and a number of mutations
within the NS5A region [12–14]. Of these, substitution of
arginine (Arg, R) by glutamine (Gln, Q) or histamine (His,
H) at amino acid 70 (R70Q/H) in the core protein and the
IL28B polymorphism have been shown to be key factors in
determining resistance for both PEG-IFNα/RBV or telapre-
vir/PEG-IFNα/RVB treatment [15–19]. For patients with
the IL28B rs8099917 genotype non-TT, only 12 % of those
with 70Q/H exhibited SVR, while 50 % of those with 70R
developed SVR [20]. However, the mechanisms that medi-
ate this association remain unclear.
Although most of these studies were performed in
Japanese patients, the geographical distribution of genotype
1b strains with core region R70Q/H and IL28B SNPs may
be substantially different. The influence of these factors on
the response to PEG-IFNα/RVB treatment might be differ-
ent. In China, about 40 million people are HCV carriers,
most of whom are infected with HCV genotype 1b.
Previously, we developed a novel detection system to
quantify the virus strains as wild-type aa70 (70R) or
mutant (70Q/H) [21]. The present study prospectively
enrolled 112 Chinese adults with chronic hepatitis C of
genotype 1b who received combination therapy with
PEG-IFNα/RVB, and the dynamic changes in 70R and
70Q/H strains during treatment were determined. The
aim of this study was to investigate: (1) the distribution
of codon 70 in Chinese patients with HCV 1b infection,
(2) whether 70Q/H strains are independently resistant to
treatment, and (3) whether substitution of amino acid 70




Table 1 summarizes the profiles and laboratory data of the
patients at the commencement of antiviral treatment. The
patient pool was comprised of 64 males and 48 females,
aged 21–75 years (mean, 45.2 years). At baseline, the mean
alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) levels were 57.3 IU/L (range, 13.9–165.5 IU/L)
and 39.8 IU/L (range, 22.6–109.0 IU/L), respectively. The
mean leukocyte counts, platelet counts, and hemoglobin
levels were 4.6 × 109/L (range, 2.9–9.1 × 109/L), 151.3 × 109/
L (range, 41–329 × 109/L), and 134.5 g/L (range, 77–168 g/
L), respectively. The mean viremia level was 6.3 log10IU/
mL (range, 5.0–7.9 log10IU/mL). There were no signifi-
cantly difference between the patients with 70R dominance
and 70Q/H dominance. However, the rs12979860 CC
genotype was associated with wild type aa70 (83.7 % vs.
60 %; P = 0.038), which was in agreement with a previous
report [17].
Virological responses and adherence
A total of 112 Chinese patients were enrolled in this
study. Eight patients discontinued therapy due to ad-
verse effects. Three of the patients (cessation at 4, 5 and
7 weeks) failed to complete follow-up after cessation of
therapy. Three patients (cessation at 15, 18 and 24 weeks)
achieved complete EVR, but failed to complete follow-
up. The other two patients achieved complete EVR, but
experienced relapse after cessation of therapy at 14 and
19 weeks respectively. The remaining 104 patients com-
pleted all 48 weeks of combination therapy and 24 con-
secutive weeks of follow-up. All 104 patients received
treatment for the expected time and adherence to both
drugs was >80 % overall. Among the 109 patients who
completed at least 12 weeks of therapy, 79.8 % (87/109)
patients exhibited EVR, 21.2 % (22/104) patients failed
to respond to the treatment (NVR), 69.2 % (72/104) of
the patients achieved SVR.
IL28B SNP genotypes
The genotypes of two IL28B SNPs (rs12979860 and
rs8099917) were measured for each patient. The result
shows that these SNPs were in complete linkage disequi-
librium and could be nearly interchangeable. Only one
patient showed an intermediate haplotype consisting of
the unfavourable genotype for rs12979860 (CT) but a
favourable genotype for rs8099917 (TT) and the patient
failed to follow-up at 15 weeks. Therefore, we selected the
rs12979860 as the tag SNP in the studies. Among the 104
patients who completed the 48 weeks of combination
therapy and 24 weeks of follow-up, the favourable geno-
type (CC) was identified in 85 patients (81.7 %), and 66 of
them (77.7 %) achieved SVR. The remaining 19 patients
were CT heterozygous, only 6(31.6 %) of them achieved
SVR. No patient carried the TT genotype in this study set.
Conversely, patients with the unfavourable genotype (CT)
were significantly more likely to show an NVR (47.4 % vs
15.3 %, P = 0.004) (Table 2).
Prevalence of substitutions of amino acid 70 at baseline
in treatment-naive Chinese patients with HCV 1b
The viral loads of HCV with 70R and the 70Q/H substitu-
tion were quantified at baseline in all 112 cases. As shown
in Fig. 1, 93.8 % (105/112) of the patients were infected
with a mixture of 70R and 70Q/H strains before treat-
ment, with the 70Q/H strain dominant in 20.5 % (23/112)
patients (Fig. 1).
Amino acid 70 substitutions at baseline were associated
with the virological response to PEG-IFNα/RBV treatment
Analysis of the relationship between the dominant
strains (70R or 70Q/H >50 %) and EVR showed that
42.9 % (9/21) of patients in whom 70Q/H was the dom-
inant strain achieved EVR compared to 88.6 % (78/88)
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of patients with 70R dominance (P < 0.001). Further-
more, 35.0 % (7/20) of patients with 70Q/H dominance
exhibited SVR, while 77.4 % (65/84) with 70R dominance
exhibited SVR (P < 0.001). Similar results were found in
patients with favourable genotype for rs12979860 (CC).
But for patients with unfavourable genotype (CT), al-
though the rates of EVR and SVR in 70R group were
higher than that in 70Q/H group, the different was not
significant due to the number of cases was too small
(Table 2).
Dynamic changes in 70R and 70Q/H during treatment
Using the serial serum samples collected at weeks 2, 4,
8, 12, and 24 during PEG-IFNα/RBV treatment, the viral
loads of HCV with 70R and the 70Q/H substitution
were quantified to assess their dynamic response to
treatment. The results are summarized in Figure 2. Most
notably, no matter the dominant strain or virological
response type, the 70Q/H strain always exhibited the
same response to treatment as the 70R strain. In patients
that exhibited a good response to treatment, the 70Q/H
viral load decreased concurrent with that of the 70R
strain (A1). If the patients failed to respond to treatment,
the viral loads of both the 70R and 70Q/H strains
showed little change (A2-3). Furthermore, the percent-
age of HCV harboring the 70Q/H substitution did not
change significantly during treatment (B1-3), even in pa-
tients that experienced virological breakthrough (B4) or
relapse (B5). Although for several patients, the percent-
age of 70Q/H increased to some extent during treat-
ment, no changes from inferior strain into the dominant
strain were found (A6, B6). And the percentage of 70R
HCV was found to be increased with treatment in sev-
eral patients (A7, B7). Furthermore, the effects of IL28B
SNP genotypes on the dynamic changes of 70R and
70Q/H were not observed in the study.
Table 1 Profile of study patients and baseline clinical features
Characteristic 70R 70Q/H P
Demographic data
Number 89 23
Gender (M/F) 52/37 12/11 0.589a
Age (years) 44.8 (8.9) 46.9 (11.0) 0.344b
History of blood transfusionc 40 (44.9 %) 12 (52.2 %) 0.535a
Laboratory data
Serum alanine aminotransferase (IU/L) 57.5 (24.6) 56.5 (20) 0.867b
Serum aspartate aminotransferase (IU/L) 40.3 (16.9) 37.9 (16.0) 0.540b
Total serum bilirubin (μmol/L) 17.0 (9.1) 18.6 (12.1) 0.476b
Serum albumin (g/L) 39.6 (5.7) 38.0 (6.1) 0.241b
γ-Glutamyl transpeptidase (IU/L) 41.9 (18.0) 40.3 (21.4) 0.725b
Triglycerides (mmol/L) 1.1 (0.5) 1.0 (0.49) 0.427b
Total cholesterol (mmol/L) 4.4 (0.57) 4.4 (0.71) 0.934b
Prothrombin time (INR) 1.01 (0.18) 1.04 (0.24) 0.495b
Prothrombin activity (%)d 91.4 (15.9) 86.3 (16.7) 0.178b
Leukocyte count (109/L) 4.75 (1.48) 4.17 (1.0) 0.082b
Platelet count ( 109/L) 154.2 (66.2) 140.2 (72.4) 0.379b
Hemoglobin (g/L) 135.7 (17.1) 129.8 (22.8) 0.172b
HCV RNA level (log10 IU/mL) 6.31 (0.66) 6.28 (0.86) 0.873b
IL28B genotype
rs12979860 77CC/12CT 15CC/8CT 0.038e
rs8099917 78TT/11TG 15TT/8TG 0.025e
Normal reference ranges: 5–40 IU/L for alanine aminotransferase; 8–40 IU/L for aspartate aminotransferase; 5–20 μmol/L for total serum bilirubin; 36–55 g/L for
serum albumin; 10–50 IU/L for γ-Glutamyl transpeptidase; 0.22–1.69 mmol/L for triglycerides; 3.9–5.7 mmol/L for cholesterol; 0.8–1.5 INR for prothrombin time;
80–120 % for prothrombin activity; 4–10 × 109/L for leukocyte count; 100–300 × 109/L for platelet count; 110–160 g/L for hemoglobin
aPearson Chi-Square Test
bIndependent-Samples T Test
Data are the mean (standard deviation) values, except those denoted by c, which represent the number (percentage) of patients
dProthrombin activity (PTA) was calculated by the patient prothrombin time (PPT) and control prothrombin time (CPT) according to the following
formula: PTA = [CPT-(CPT × 0.6)]/[PPT-(CPT × 0.6)] × 100 %
eContinuity Correction Chi-Square Test
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Figure 3 shows the dynamic changes in the percentage
of HCV harboring the 70Q/H substitution in all 112
patients during PEG-IFNα/RBV therapy. No changes
from inferior strain into the dominant strain were found.
Furthermore, the samples shown in Figure 2 were sub-
jected to TA cloning and sequencing when HCV RNAs
were detectable. A total of 480 clones (20 for each time
point) were picked, sequenced, and analyzed. The results
showed that the percentages of 70R at each time point
were comparable to the ratios of 70R to 70Q/H deter-
mined by cloning sequencing. No positive selection ef-
fect was observed for either 70Q/H or 70R (Table 3).
Discussion
HCV infection is a worldwide healthcare problem, but
its prevalence differs among geographic regions [22]. In
China, although hepatitis B virus (HBV) infection is the
main cause of viral hepatitis, HCV infection is also a ser-
ious problem [23, 24]. According to a sero-epidemiological
study on hepatitis C in China carried out in 2006, the
overall prevalence of anti-HCV was 0.43 % (95 % CI: 0.33–
0.53 %) among the population aged 1 year to 59 years of
age [25]. Thus, the prevalence of HCV infection in China is
low. However, given China’s population base of 1.34 billion,
the number of HCV-infected patients is estimated to be
nearly 40 million, and approximately 60 % of HCV patients
are infected with genotype 1b. Because safer and more
effective DAAs are still not available in China, PEG-IFNα/
RBV combination therapy is still the standard treatment for
these patients.
Several factors have been associated with the failure to
respond to PEG-IFNα/RBV therapy and the incidence of
post-treatment relapse. Of these, substitution of amino
acid 70 in the core protein is one of the most important
factors [15–19]. Several studies [26–28] have shown that
the substitution of R70Q/H is more common in non-
virological responders (NVRs), and that decreases in the
levels of HCV RNA during treatment were significantly
less in patients with 70Q/H than in patients with 70R.
Amino acid substitution of R70Q/H in patients with
HCV 1b had a significant effect on combination therapy
in NVRs. However, most of these data were derived from
Table 2 Virological response by IL28B genotypes and HCV core protein aa70 substitutions
rs12979860 Core 70 EVR P SVR P NVR P
CC 76/89 (85.4 %) 0.005a 66/85 (77.7 %) <0.001b 13/85 (15.3 %) 0.004a
CT 11/20 (55.0 %) 6/19 (31.6 %) 9/19 (47.4 %)
Wild type 78/88 (88.6 %) <0.001a 65/84 (77.4 %) <0.001b 10/84 (11.9 %) <0.001a
Mutant 9/21 (42.9 %) 7/20 (35.0 %) 12/20 (60.0 %)
CC Wild type 69/76 (90.8 %) 0.003a 61/73 (83. 6 %) 0.004a 7/73 (9.6 %) 0.002a
Mutant 7/13 (53.9 %) 5/12 (41.7 %) 6/12 (50.0 %)
CT Wild type 9/12 (75.0 %) 0.065a 4/11 (36.4 %) 1.000a 3/11 (27.3 %) 0.07a
Mutant 2/8 (25.0 %) 2/8 (25.0 %) 6/8 (75.0 %)
EVR early virological response; SVR sustained virological response; NVR non-virological response
aFisher’s Exact Test
bPearson Chi-Square Test
Fig. 1 Percentage of 70R and 70Q/H strains in each patient before therapy
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Fig. 2 (See legend on next page.)
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studies performed in Japan, and the exact mechanisms
of this association remain unclear. For example, it re-
mains to be determined whether substitution of R70Q/H
is still useful in predicting virological responses in Chin-
ese patients. Differences in the response of 70Q/H
strains to treatment compared to that of 70R strains also
remain to be characterized, as does whether these mu-
tant strains are independently resistant to treatment.
Finally, whether substitution of aa70 is due to selection
pressure resulting from PEG-IFNα/RBV treatment re-
mains to be determined.
Previously, we developed a TaqMan two step real time
RT-PCR system using degenerate TaqMan-MGB probes
with inosine to quantify the genotypes of HCV aa70.
The degenerate probes could detect 1 % of 70R or 70Q/
H in the mixture with a detection limit of 103 copies/
mL. Cross-reactivity tests confirmed the specificity of
this assay, and further cloning and sequencing analyses
confirmed the reliability of the system. Using this quanti-
tative system, the analysis of serial serum samples from
112 Chinese patients with chronic HCV 1b infection who
received PEG-IFNα/RBV therapy brought us surprising
(See figure on previous page.)
Fig. 2 Dynamic changes in 70R and 70Q/H levels before and during PEG-IFNα/RBV treatment. a. Viral loads of 70R and 70Q/H strains (Log10 copies/
mL). b. Percentage of 70R and 70Q/H strains (%). A1/B1: Patient 42 with dominant 70R achieved EVR (rs12979860 CC genotype). A2/B2: Patient 99 with
dominant 70R had no response to treatment (rs12979860 CT genotype). A3/B3: Patient 9 with dominant 70Q/H had no response to treatment
(rs12979860 CC genotype). A4/B4: Patient 21 with dominant 70Q/H achieved EVR but experienced breakthrough during treatment (rs12979860 CC
genotype). A5/B5: Patient 106 with dominant 70R achieved EVR but discontinued therapy due to adverse events at weeks 19 and relapsed quickly
(rs12979860 CC genotype). A6/B6: Patient 60 with dominant 70R achieved EVR (rs12979860 CC genotype). A7/B7: Patient 25 with dominant 70R
achieved EVR (rs12979860 CT genotype)
a
b
Fig. 3 Dynamic changes in the percentage of the 70Q/H strain during treatment. a. Patients with 70Q/H dominance; b. Patients with 70R dominance
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and interesting results. Contrary to our original hypoth-
esis, most patients were infected with mixtures of 70R and
70Q/H strains, and the 70R strain was dominant (79.5 %
of patients) before treatment.
Among all the 104 patients who completed the 48 weeks
of combination therapy and 24 consecutive weeks of
follow-up, 69.2 % (72/104) of the patients achieved SVR,
which is relatively higher than previously reported in
Japan, Europe and the United States. The reason may be
that the frequency of favourable genotype (CC) of IL28B
SNPs (rs12979860) in Chinese patients is much higher
than that in Japanese or Aframerican and more likely to
achieve a SVR. In this study, 81.7 % of the patients were
found to be the favourable genotype (CC) and 77.7 % of
them achieved SVR.
Although 35.0 % of patients with dominant 70Q/H
achieved SVR, while 77.4 % with dominant 70R exhibited
SVR, the viral kinetics of 70R and 70Q/H always changed
synchronously during treatment, no matter which strain
was dominant or which genotype was the IL28B SNP. The
70Q/H strain was not independently resistant to PEG-
IFNα/RBV treatment. If patients responded to treatment,
the viral loads of 70Q/H decreased as well as those of
70R, while if the patients failed to respond, both the 70R
and 70Q/H strains resisted treatment.
However, this finding does not mean that aa70 sub-
stitutions have no effects on the action of IFNα. Pre-
vious studies [29–32] reported that HCV core protein
might be associated with resistance to IFN therapy
involving the Jak-STAT signaling pathway. A study
[33] also reported that aa substitutions in the core re-
gion might affect some proteins involved in resistance
to IFNα therapy, such as SOCS proteins, which is
known to inhibit IFNα-induced activation of the Jak-
STAT pathway and expression of the antiviral pro-
teins 2′,5′-OAS and MxA. Further study [34] showed
that HCV R70 core mutants were resistant to IFN in
vitro, and the resistance may be induced by IL-6-
induced upregulation of SOCS3. These mechanisms
can explain clinical IFNα resistance in patients with
HCV core mutants, but are not consistent with our
data showing that core 70R and core 70Q/R respond
similarly during treatment. Unlike DAAs, which in-
hibit the replication of HCV directly, IFNα exerts
antiviral effects by inducing the expression of antiviral
proteins. Presumably, if 70R and 70Q/H exist in a
single hepatic cell, the both 70R and 70Q/H core pro-
teins will be expressed. Only when the 70Q/H core
protein is dominant, the expression of antiviral pro-
teins induced by interferon will be down-regulated
significantly, and thus influence the inhibition of not
only 70Q/H, but also the 70R strains. However, this
has yet to be confirmed. An alternative explanation is
that R70Q/H substitution alone is not sufficient to
produce resistance to IFNα. Ikeda et al. [35] designed
a study to examine the differences among the anti-
viral activities of HCV core proteins with various sub-
stitutions at aa70 and/or aa91 in vitro. Retroviral
vectors expressing the HCV core proteins with substi-
tutions of arginine/leucine, arginine/methionine, glu-
tamine/leucine or glutamine/methionine at aa70/aa91
were transiently transfected or stably transduced into
an immortalized hepatocyte line (PH5CH8), hepatoma
cell lines, and an HCV-RNA replicating cell line
Table 3 Ratio of 70R to 70Q/H during treatment determined by cloning and sequencing
Patients 0 W 2 W 4 W 8 W 12 W 24 W
70R Codon 70 70R Codon 70 70R Codon 70 70R Codon 70 70R Codon 70 70R Codon 70






/ / / / / /















A3/B3 3.7 % 18CAG/2 N.D. 2.4 % 17CAG/
1CGT/2 N.D.





2.4 % 19CAG/1 N.D.
A4/B4 9.7 % 2CGG/18CAA / / / / / / / / 6.2 % 1CGG/18CAA/
1 N.D.
A5/B5 98.5 % 4CGG/14CGA/
1CAG/1 N.D.
/ / / / / / / / 99.0 % 4CGG/13CGA/
3 N.D.
A6/B6 89.9 % 18CGG/2CAG 82.5 % 17CGG/
3CAG
/ / / / / / / /







/ / / / / /
N.D., no data available due to sequencing failure
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(sOR) to evaluate the antiviral responses to IFN-α or
IFN-α/RBV. The results showed that the promoter ac-
tivity levels of IFN-stimulated genes in the transiently
transfected cells or the mRNA levels of 2′-5′-oligoa-
denylate synthetase in the stably transduced PH5CH8
cells were not associated with HCV core aa70 and/or
aa91 substitutions during IFNα treatment. Antiviral
responses to IFNα or IFNα/RBV treatment were en-
hanced in sOR cells stably transduced with the HCV
core, although there were no differences in antiviral
responses among the cells expressing different core
types. Furthermore, Hiraga N, et al.[36] found that
core aa70 substitutions did not impaired the infectiv-
ity and replication ability of infectious HCV genotype
1b clone HCV-KT9 in human hepatocyte chimeric
mice, and the effect of IFN treatment was similar in
wild-type and mutant viruses. These results were in
agreement with those of our clinical studies. There-
fore, the detailed mechanism should be investigated
further to clarify the discrepancy between these
studies.
In addition, dynamic changes in the proportions of
70R and 70Q/H strains during treatment showed that
the ratios of 70Q/H to 70R did not change significantly.
Although for several patients, the percentage of 70Q/H
increased to a small extent, no changes from inferior
strain into the dominant strain were found. As a result,
no evidence of positive selection for the core 70Q/H
variant induced by PEG-IFNα/RVB treatment was ob-
served in the present study. This disagrees with a previ-
ous report investigating the viral factors associated with
treatment failure determined by direct and cloning
sequencing that indicated that treatment-induced selec-
tion occurred in all nonresponsive patients who har-
bored 70Q quasispecies detectable by cloning [37]. The
discrepancy between these two studies may be associated
with the detection methods, ethnic and genetic differ-
ences, or some unexplained mechanism.
Conclusions
Most Chinese patients with HCV 1b examined in this
study were infected with a mixture of 70R and 70Q/H
strains before treatment. Assessment of the dynamic
changes in the proportion of 70R and 70Q/H strains
during PEG-IFNα/RBV therapy showed that 70Q/H had
similar response to PEG-IFN/RBV therapy as 70R and
indicated that substitution of R70Q/H is not enough to
lead to resistance to IFNα. No evidence of positive selec-
tion for 70Q/H induced by treatment with PEG-IFNα/
RBV was observed. Furthermore, IL28B SNP genotypes
were not associated with the dynamic changes of 70R and
70Q/H strains during PEG-IFNα/RBV therapy. However,
the ratio of 70Q/H to 70R and IL28B polymorphism
might have an effect on virological response to treatment.
Further studies are required to investigate the detailed
mechanism of this association.
Methods
Ethics statement
The study protocol conformed to the ethical guidelines
of the Declaration of Helsinki and was approved by The
Ethical Committee of Beijing Youan Hospital, Capital
Medical University. Written informed consent was ob-
tained from each patient participating in this study.
Patient population
Between January 2009 and June 2013, 112 Chinese pa-
tients with chronic HCV 1b infection were enrolled in
this study at Beijing Youan Hospital, Capital Medical
University. Patients were prospectively selected based on
the following criteria: (1) levels of HCV RNA greater
than 1 × 105 IU/mL as measured with TaqMan real time
PCR (Amplicor, Roche Diagnostic Systems, Shanghai,
China); (2) naive to antiviral treatment; (3) free of coin-
fection with hepatitis B virus or human immunodefi-
ciency virus; (4) free of HCC based on laboratory tests
and imaging studies; and (5) free of other causes of liver
disease, such as alcoholic liver disease, autoimmune liver
disease, drug induced liver injury, hemochromatosis, or
Wilson’s disease.
All patients enrolled in this study received a standard
protocol of 48 weeks of combination therapy with PEG-
IFNα-2b (1.5 mg/kg of body weight by subcutaneous in-
jection once per week) plus RBV (600–1200 mg daily,
according to body weight) and 24 consecutive weeks of
follow-up. All patients underwent HCV RNA testing at
weeks 4, 8, 12, 24, and 48 of therapy. Follow-up testing
was performed at week 72. When needed, doses of PEG-
IFNα-2b and RBV were reduced on an individual basis
during treatment to lessen adverse effects, and these
dose reductions were performed according to the guide-
lines for the treatment of hepatitis C in China.
Serum samples
Blood samples were obtained at least once within the
month before treatment. During combination therapy,
blood samples were obtained at weeks 2, 4, 8, 12, and
24. Serum samples were frozen at −80 °C within 4 h of
collection and thawed at the time of measurement.
Definition of virological responses
Virological responses during therapy were defined based
on the results of HCV RNA analysis. Early virological
response (EVR) was defined as a more than two log re-
duction in HCV RNA levels compared to baseline (par-
tial EVR) or as HCV RNA negative at treatment week 12
(complete EVR). Sustained virological response (SVR)
was defined as undetectable levels of HCV RNA 24 weeks
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after cessation of treatment. Breakthrough was defined as
the reappearance of HCV RNA in serum while still on
therapy. Relapse was defined as the reappearance of HCV
RNA in the serum after therapy was discontinued. Non-
virological response (NVR) was defined as failure to clear
HCV RNA from the serum after 24 weeks of therapy.
HCV RNA extraction and reverse transcription
HCV RNA was extracted from the serum samples
(140 μL) using the QIAamp Viral RNA Mini Kit (Qiagen,
Shanghai, China), and cDNA was prepared by reverse
transcription with random hexamers using TaqMan Re-
verse Transcription Reagents (Applied Biosystems). The
reaction conditions were 25 °C for 10 min, 42 °C for
40 min, and 95 °C for 5 min.
IL28B SNP genotyping
Two IL28B SNPs, rs12979860 and rs8099917 were geno-
typed for each patient as previously described [38].
Briefly, human genomic DNA was extracted from per-
ipheral blood cells by a QIAamp DNA Mini Kit (Qia-
gen). Genotyping of the rs12979860 and rs8099917 was
performed using direct sequencing. Nucleic acids were




AAATGAGAGATA-3′). Amplicons were purified with a
QIAquick PCR Purification Kit (Qiagen) after agarose
gel electrophoresis and then used for direct sequencing
(Beijing AuGCT DNA-SYN Biotechnology Co. Ltd).
Quantification of HCV RNA with 70R and 70Q/H
Previously, we developed a TaqMan two-step real time
RT-PCR system for the quantification of HCV RNA with
70R and 70Q/H using degenerate TaqMan-minor groove
binder (MGB) probes with inosine [21]. According to
the proportions of codon 70 types in the HCV 1b gene
from genetic databases [39], the degenerate probes can
be used to detect 99.6 % of patients with HCV 1b. Using
this method, 70R and 70Q/H viral RNAs can be quanti-
fied and their dynamic responses to PEG-IFNα/RBV
therapy assessed.
The detection system used is as follows. Based on the
consensus sequence of the HCV 1b core gene identified
previously [39], a primer pair was designed based on the
conserved regions. Meanwhile, two degenerate TaqMan-
MGB probes with inosine (I) were designed to distin-
guish between the 70R (CGN) and 70Q/H (CAN) co-
dons. Real time PCR was performed in a final volume of
50 μL containing 5 μL of the cDNA reaction mixture,
0.3 μM of each primer, 0.1 μM probes, and 25 μL 2 ×
LightCycler® 480 Probes Master Mix (Roche Applied Sci-
ence, Shanghai, China). Two separate reaction systems
were prepared to detect 70R and 70Q/H, respectively,
but the two reactions were carried out simultaneously on
the same real time PCR system. The cycle conditions were
as follows: an initial denaturation for 10 min at 95 °C,
followed by 45 cycles of denaturation for 15 s at 95 °C,
and an annealing/extension step for 1 min at 60 °C. All
reactions were performed in triplicate on a LightCycler®
480 Real-Time PCR System (Roche Applied Science) and
the results were analyzed using LightCycler® 480 Software
(Roche Applied Science).
Nucleotide sequencing of the HCV core gene
The ratio of 70R and 70Q/H was confirmed by cloning
and sequencing some of the patients. Cloning was
carried out using TOPO TA Cloning Kits (Invitrogen),
according to the manufacturer’s protocol. PCR was per-
formed using 5′-TCGTGGAAGGCGACAACC-3′ and
5′-GCCGACGAGCGGAATGT-3′ as the sense and anti-
sense primers, respectively. A total of 20 colonies for
each sample were selected at random and sequenced
(Beijing AuGCT DNA-SYN Biotechnology Co., Ltd).
Statistical Analysis
The one-sample Kolmogorov-Smirnov test was used to
test the normality of the baseline clinical data. The rela-
tionship between the dominant strain and the virological
response was analyzed by Chi-square tests and Fisher’s
exact probability test with a 4-fold table. A P-value of
<0.05 was considered statistically significant. Statistical
analyses were performed using SPSS software (SPSS Inc.,
Chicago, IL).
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